Sarepta Therapeutics, Inc. (SRPT)
Automate Your Wheel Strategy on SRPT
With Tiblio's Option Bot, you can configure your own wheel strategy including SRPT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SRPT
- Rev/Share 22.9388
- Book/Share 11.7368
- PB 1.7841
- Debt/Equity 1.1759
- CurrentRatio 4.0168
- ROIC -0.062
- MktCap 2057920380.0
- FreeCF/Share -7.0618
- PFCF -2.9931
- PE -8.208
- Debt/Assets 0.3878
- DivYield 0
- ROE -0.2
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | SRPT | Wolfe Research | -- | Peer Perform | -- | -- | June 17, 2025 |
| Downgrade | SRPT | BofA Securities | Buy | Neutral | -- | -- | June 16, 2025 |
| Downgrade | SRPT | Cantor Fitzgerald | Overweight | Neutral | -- | -- | June 16, 2025 |
| Downgrade | SRPT | BMO Capital Markets | Outperform | Market Perform | -- | $70 | June 16, 2025 |
| Downgrade | SRPT | H.C. Wainwright | Neutral | Sell | -- | $10 | June 16, 2025 |
| Downgrade | SRPT | Morgan Stanley | Overweight | Equal Weight | -- | -- | June 16, 2025 |
| Downgrade | SRPT | Piper Sandler | Overweight | Neutral | -- | $36 | June 16, 2025 |
| Upgrade | SRPT | Scotiabank | Sector Perform | Sector Outperform | -- | -- | June 6, 2025 |
| Downgrade | SRPT | Evercore ISI | Outperform | In-line | -- | $50 | May 8, 2025 |
| Initiation | SRPT | Wells Fargo | -- | Overweight | -- | $115 | April 11, 2025 |
News
Down To Levels Not Seen Since 2016: Initiating Sarepta With A Buy
Published: June 16, 2025 by: Seeking Alpha
Sentiment: Neutral
Sarepta Therapeutics, Inc. plunged over 47% after a second ELEVIDYS-related patient death, raising serious safety concerns and leading to trial suspensions. Despite the negative headlines and slashed FY25 guidance, I see the current valuation as deeply oversold and think long-term investors are best positioned to add at current levels. ELEVIDYS revenue dipped sequentially but remains up 180% year-over-year, and overall product revenue grew 70%, in my opinion, reflecting underlying business strength.
Read More
Sarepta Therapeutics Stock Alert: Investors of Sarepta May Have Legal Claims and Are Encouraged to Contact Kehoe Law Firm, P.C. - SRPT
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
PHILADELPHIA, PA / ACCESS Newswire / June 16, 2025 / Kehoe Law Firm, P.C. is investigating potential violations of federal securities laws and claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta") (NASDAQ:SRPT).
Read More
SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Negative
Sarepta's shares sink as second Elevidys-linked death triggers safety concerns, dosing halts and trial pauses.
Read More
Sarepta Therapeutics stock drops following second death linked to gene therapy Elevidys
Published: June 16, 2025 by: Proactive Investors
Sentiment: Negative
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares plunged almost 45% after the company disclosed the death of a second patient from acute liver failure linked with its experimental gene therapy Elevidys for Duchenne muscular dystrophy (DMD). In response, the company is convening an independent expert panel to evaluate and develop an enhanced immunosuppressive regimen, including sirolimus, to reduce the risk of acute liver failure in non-ambulatory DMD patients treated with Elevidys, with any new protocol subject to Food and Drug Administration (FDA) review and approval.
Read More
Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity
Published: June 16, 2025 by: Seeking Alpha
Sentiment: Negative
Sarepta's stock has plunged due to safety concerns with ELEVIDYS, including two deaths in non-ambulatory DMD patients and regulatory uncertainty. Despite these setbacks, ELEVIDYS remains effective for ambulatory patients, and Sarepta is proactively addressing safety via enhanced immunosuppression and trial amendments. Valuation appears depressed, with the market pricing in a worst-case scenario, but historical precedent (ZOLGENSMA) suggests recovery is possible if risks are managed.
Read More
Why Is Sarepta Therapeutics (SRPT) Up 7.7% Since Last Earnings Report?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Read More
FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
With FDA platform technology designation for its viral vector, SRPT can fast-track other therapies using the same gene-delivery method.
Read More
U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta's Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4
Published: June 04, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy type 2E/R4, has been granted platform technology designation by the U.S. Food & Drug Administration. “This is one of the first programs to receive platform technology designation.
Read More
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
Published: May 21, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy. We have received feedback from the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) that dosing may continue uninterrupted in ENVISION, study SRP-9001-303. EN.
Read More
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
Published: May 16, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported new results from Study 9001-103. Also known as ENDEAVOR, Study 9001-103 is a multi-cohort study of ELEVIDYS (delandistrogene moxeparvovec-rokl) for the treatment of Duchenne muscular dystrophy. Treatment with ELEVIDYS in the ENDEAVOR participants in cohort 6 who were 2 years old at the time of treatment (n=6), demonstrated mean expression of 93.
Read More
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
Published: May 13, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved ELEVIDYS (delandistrogene moxeparvovec) for the treatment of Duchenne muscular dystrophy (DMD) under the conditional and time-limited approval pathway in Japan. ELEVIDYS is approved for individuals ages 3- to less than 8-years-old, who do not have any deletions in exo.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
SRPT reports mixed first-quarter 2025 results. The stock plunges after the company significantly lowers its 2025 sales guidance.
Read More
Sarepta Therapeutics, Inc. (SRPT) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Mary Jenkins - Associate Director, IR Doug Ingram - President and CEO Dallan Murray - EVP, CCO Louise Rodino-Klapac - EVP, Head of R&D, CSO Ian Estepan - EVP, CFO Conference Call Participants Tazeen Ahmad - Bank of America Securities Ritu Baral - TD Cowen Louise Chen - Scotiabank Andrew Tsai - Jefferies Eliana Merle - UBS Brian Abrahams - RBC Capital Markets Debjit - Guggenheim Securities Salveen Richter - Goldman Sachs Brian Skorney - Baird Michael Ulz - Morgan Stanley Gil …
Read More
Compared to Estimates, Sarepta Therapeutics (SRPT) Q1 Earnings: A Look at Key Metrics
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Sarepta Therapeutics (SRPT) came out with a quarterly loss of $3.42 per share versus the Zacks Consensus Estimate of $0.35. This compares to earnings of $0.73 per share a year ago.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: May 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: May 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: April 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta Therapeutics, Inc. – SRPT
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Published: April 24, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , April 24, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: April 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: April 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: April 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: April 15, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
NASDAQ: SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Published: April 09, 2025 by: Business Wire
Sentiment: Neutral
RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) (“Sarepta”). On March 18, 2025, Sarepta issued a press release revealing that a 16-year-old boy had passed away from acute liver failure following treatment with Sarepta's gene therapy, ELEVIDYS. On this news, Sarepta's stock price fell $27.81 per shar.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: April 08, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: April 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
About Sarepta Therapeutics, Inc. (SRPT)
- IPO Date 1997-06-04
- Website https://www.sarepta.com
- Industry Biotechnology
- CEO Mr. Douglas S. Ingram Esq.
- Employees 1372